Trusted Resources: Education
Scientific literature and patient education texts
Treatment Patterns and Health Care Resource Utilization Among Patients With Relapsed/Refractory Systemic Light Chain Amyloidosis
source: Amyloid: The International Journal of Experimental and Clinical Investigation
year: 2018
authors: Hari P, Lin HM, Asche CV, Ren J, Yong C, Luptakova K, Faller DV, Sanchorawala V
summary/abstract:Background:
Treatment for patients with systemic light chain (AL) amyloidosis remains challenging. Our study aims to describe treatment patterns for both newly diagnosed and relapsed/refractory AL (RRAL) amyloidosis, and to assess clinical outcomes, healthcare costs, and resource utilization during the first year following a diagnosis of RRAL amyloidsis.
Methods:
This was a retrospective observational study of adult patients with AL amyloidosis using the US Optum administrative claims data during 1/1/2008 to 6/30/2015. Diagnosis was based on both ICD-9 codes and treatments with a claim for AL-amyloidosis-specific anticancer systemic agents.
Results:
Of 334 patients with AL amyloidosis, 43.1% were considered as RRAL amyloidosis. The majority (75%) of RRAL amyloidosis patients had organ involvement prior to the second line treatment. Proteasome-inhibitor-based regimens were most frequently used (41.0% for first-line AL, 30.6% for RRAL amyloidosis). Organ deterioration and mortality rates were 49.3% and 10.4%, respectively, during the two years following relapse. The average monthly cost was $14,369 per patient for RRAL amyloidosis including medical costs ($9441) and drug costs ($4928).
Conclusions:
RRAL amyloidosis is associated with high morbidity from target organ failure and mortality, which emphasizes the need for novel medications to improve care for patients with RRAL amyloidosis.
organization: Medical College of Wisconsin, USA; Millennium Pharmaceuticals, Inc., USA; University of Illinois College of Medicine at Peoria, USA; University of Illinois at Chicago College of Pharmacy, USA; Boston University School of Medicine and Boston Medical Center, USADOI: 10.1080/13506129.2017.1411796
read more
Related Content
-
How Can I Avoid Fluid Balance Problems?Many patients with AL amyloidosis should...
-
Why is Fluid Balance so Important for Amyloidosis Patients?Fluid overload is the most common seriou...
-
Keith E. Stockerl-Goldstein, MDKeith E. Stockerl-Goldstein is a Profess...
-
Therapeutic Oligonucleotides Targeting Liver Disease: TTR AmyloidosisThe liver has become an increasingly int...
-
Todd Michael Koelling, MDTodd Michael Koelling joined the Univers...
-
Safety and Efficacy of Long-Term Diflunisal Administration in Hereditary Transthyretin (ATTR) AmyloidosisBackground: A recent 2-year randomized ...
-
Steroids – ASG Webinar 4/13https://www.youtube.com/watch?v=4gUXPbOk...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.